Crystagen
Preclinical ResearchCrystagen (Glu-Asp-Pro)
A Khavinson bioregulator tetrapeptide researched for immune system regulation and thymic function.
Dose
0.1 mg
Route
Subcutaneous injection
Cycle
10-20 days
Storage
2°C to 8°C (refrigerator)
What is Crystagen?
Crystagen is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Pro. It is classified as a Khavinson peptide, which are short peptides developed based on the theory of peptide regulation of gene expression and protein synthesis. Research on Crystagen primarily focuses on its potential role in modulating immune function and promoting tissue regeneration, particularly within the lymphatic system and thymus. Studies are largely preclinical (animal and in-vitro) with some smaller human observational studies, suggesting potential for use in conditions involving immune dysregulation or accelerated aging. It is designed to act on specific cellular processes, aiming to restore physiological function.
Key Benefits
- Immune regulation research
🐾 Griffin Says...
Molecular Information
Molecular weight
488.48 g/mol
Type
Synthetic tetrapeptide bioregulator
Amino acid sequence
Lys-Glu-Asp-Pro
Lysine-Glutamic acid-Aspartic acid-Proline
Pharmacokinetics
Time to peak
15-30 minutes (animal data for similar peptides)
Half-life
0.5 h
Time to clear
Within a few hours
V. Khavinson, Peptides and Ageing (2002); Khavinson VKh, et al. Gerontology (1999).
Research Indications
Thymic Regulation
Animal and in-vitro studies suggest Crystagen may support thymic function and T-cell differentiation, particularly in models of age-related thymic involution. (Evidence: Animal/in-vitro only, smaller human studies)
Immune Homeostasis
Research indicates potential for balancing immune responses, including humoral and cellular immunity, especially in conditions associated with immune deficiency or chronic stress. (Evidence: Animal/in-vitro only, smaller human studies)
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Immune Support Research | 0.1 mg | Once daily | Subcutaneous injection |
| Thymic Function Research (Long-term) | 0.1 mg | Once daily for 10-20 days, repeated every 4-6 months | Subcutaneous injection |
| Lymphatic System Regeneration Research | 0.05 - 0.1 mg | Once daily | Subcutaneous injection |
| Cellular Stress Response Research (Acute) | 0.1 mg | Once daily for 5-10 days | Subcutaneous injection |
Adherence to specific cycle lengths and breaks is considered important for observing the intended modulatory effects and avoiding potential downregulation of desired responses.
Peptide Interactions
- Use Caution
Immunosuppressants
Crystagen's potential immunomodulatory effects could theoretically alter the efficacy or side effects of immunosuppressive agents. Monitor immune markers closely in co-administration studies. (Evidence: Theoretical)
- Monitor Combination
Other Bioregulator Peptides
Combinations with other Khavinson bioregulators are sometimes explored in research protocols for synergistic effects; however, specific interaction profiles vary, and careful monitoring of outcomes is advised. (Evidence: Research protocol practice, limited specific interaction data)
- Use Caution
Corticosteroids
Due to corticosteroids' broad immunosuppressive actions, co-administration with an immune-modulating peptide like Crystagen requires careful evaluation of potential counteracting effects or altered outcomes. (Evidence: Theoretical)
- Use Caution
Antineoplastic Agents (Chemotherapy)
Research involving Crystagen in conjunction with chemotherapy aims to mitigate immunosuppression. However, potential interactions are complex and require rigorous preclinical and clinical investigation. (Evidence: Limited preclinical exploration, theoretical)
How to Reconstitute
- 1Gather supplies: lyophilized Crystagen vial, bacteriostatic water for injection, sterile syringe (e.g., 1mL), sterile needle (e.g., 23-25 gauge), alcohol swabs.
- 2Clean hands thoroughly with soap and water or an alcohol-based hand sanitizer.
- 3Swab the rubber stopper of the Crystagen vial and the bacteriostatic water vial with alcohol swabs and allow to air dry.
- 4Draw the desired volume of bacteriostatic water (e.g., 1 mL) into the sterile syringe.
- 5Slowly inject the bacteriostatic water into the Crystagen vial, aiming the stream down the side of the vial to minimize direct impact on the lyophilized powder.
- 6Do not shake the vial. Gently swirl or roll the vial between your palms for several minutes until the powder is completely dissolved, ensuring no visible particles remain.
- 7Once dissolved, inspect the solution for clarity and absence of particulate matter. Store the reconstituted solution as directed.
Slow, gentle mixing is crucial to preserve peptide integrity. Avoid shaking or aggressive agitation.
What to Expect
- Gradual onset of observed effects over days to weeks, rather than immediate, acute changes.
- Improved markers of immune system activity in research subjects (e.g., specific lymphocyte populations) in some animal and limited human studies.
- Potential for subjective improvements in vitality or well-being reported in some human observational studies.
- No immediate 'feeling' or sensation upon administration is typically reported.
- Local site reactions such as mild redness, itching, or swelling at the injection site may occur.
Side Effects & Safety
- All research involving Crystagen should be conducted in a controlled laboratory environment by trained professionals.
- Sterile technique must be strictly followed during reconstitution and administration to prevent contamination.
- Research subjects should be monitored for any unexpected adverse reactions or changes in health status.
- Always use a fresh, sterile needle and syringe for each administration.
- Proper disposal of all sharps and medical waste according to institutional guidelines is required.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.